The protective efficacy of locally prepared combined inactivated *Mycoplasma gallisepticum* and *Pasteurella multocida* vaccine in chickens

*Fatma F. Ibrahim*¹, Wafaa A. Abd El-Ghany², Eman M. El Rawy¹, Mona M. Shaker³ and El-Jakee J².

¹ Veterinary Serum and Vaccine Research Institute, Abbasia, Cairo, Egypt
² Faculty of Veterinary Medicine, Cairo University, Cairo, Egypt
³ Animal Health Research Institute, Dokki, Giza, Egypt

*Correspondence: dr.fatma_vet@yahoo.com* Accepted: 23 Apr. 2018 Published online: 23 May. 2018

The present work was planned to study the immune response and protection of chickens vaccinated with locally prepared combined inactivated vaccine of *Mycoplasma gallisepticum* (*M. gallisepticum*) and *Pasteurella multocida* (*P. multocida*) adjuvanted with Montanide ISA70. The prepared vaccine was evaluated by measurement of nitric oxide in the supernatant of macrophage, Enzyme Linked Immuno sorbent assay (ELISA) and challenge tests. The results showed that combined inactivated vaccine of *M. gallisepticum* and *P. multocida* induced high and long duration of antibody response and significant protection against the challenge with virulent strain of *M. gallisepticum*.

**Keywords:** *M. gallisepticum*, *P. multocida*, vaccine, chicken, Montanide ISA70.

**INTRODUCTION**

*Mycoplasma gallisepticum* is a bacterial pathogen of poultry that is estimated to cause annual losses exceeding $780 million. The National Poultry Improvement Plan guidelines recommend regular surveillance and intervention strategies to contain *M. gallisepticum* infections and ensure mycoplasma-free avian stocks (Hennigan et al., 2012). *M. gallisepticum* is a significant poultry pathogen involved in severe economic losses of the poultry industry due to a reduction in egg production, hatchability and downgrading of carcasses. Both horizontal and vertical disease transmission leads to rapid spreading of this pathogen in flocks. *M. gallisepticum* can cause severe chronic respiratory disease (CRD) when present in concert with other poultry pathogens including Newcastle disease virus, Infectious bronchitis virus and *E. coli* (Stipkovits et al., 2012). Infections with *Avibacterium paragallinarum* and *Pasteurella multocida* (*P. multocida*) should also be ruled out (OIE, 2012).

Control of pathogenic avian mycoplasmas can consist of one of three general approaches; Maintaining flocks free of infection, medication, or vaccination. Medication can be very useful in preventing clinical signs and lesions, as well as economic losses, but cannot be used to eliminate infection from a flock and is therefore not a satisfactory long-term solution. Vaccination against *M. gallisepticum* can be a useful long-term solution in situations where maintaining flocks free of infection is not feasible, especially on multi-age commercial egg production sites (Kleven, 2008). Effective method to prevention of this infection is vaccination by inactivated vaccines (Ferguson-Noel et al., 2012). The major advantage of bacterins is their safety. Live attenuated vaccines may have residual pathogenicity or may revert to
the status before attenuation (El Gazzar et al., 2011). Otherwise Ley (2008) stated that bacterins are considered to be of minimal value in the long-term control of *M. gallisepticum* infection in multiple-age commercial layer production sites. Also Faruque and Christensen (2007) concluded that inoculation of inactivated *M. gallisepticum* vaccine is not justified and is too expensive at farm levels.

*P. multocida* is a major animal pathogen that causes a range of diseases including fowl cholera. *P. multocida* infections result in considerable losses to layer and breeder flocks in poultry industries worldwide. *P. multocida* lipopolysaccharide (LPS) is a primary stimulator of the host immune response and a critical determinant of bacterin protective efficacy (Harper et al., 2016).

So the aim of this study was to study the potency of the locally prepared combined inactivated vaccine of *M. gallisepticum* and *P. multocida* adjuvanted with Montanide ISA70 against *M. gallisepticum*.

**MATERIALS AND METHODS**

Preparation of combined inactivated oil emulsion vaccine of *M. gallisepticum* and *P. multocida*:

Equal parts (V/V) of the inactivated broth of *M. gallisepticum* [field isolate of *M. gallisepticum* (Eis3-10) was kindly obtained from Mycoplasma Department, Animal Health Research Institute, Dokki, Giza, Egypt] and *P. multocida* strains (serotypes A and D were kindly obtained from Aerobic Bacterial Vaccines Department, Veterinary Serum and Vaccine Research Institute, Abbassia, Cairo) were mixed using a magnetic stirrer. Aforementioned suspension was adjusted its concentration to contain $3 \times 10^{10}$ colony forming unit (C.F.U.) per dose (5% packed cell volume) of *M. gallisepticum* according to Yoder (1979) and $3.25 \times 10^{10}$ C.F.U./ml of each strain of *P. multocida* according to Mukkur et al., (1982). Equal amounts of aforementioned culture and Montanide ISA70 oil (SEPPIC, France) were mixed thoroughly in a ratio of 50/50 using a magnetic stirrer at approximately 300 rpm for 15 minutes (water-in-oil emulsions).

Evaluation and quality control of the vaccine:

The vaccine was tested for purity, sterility, safety and potency tests according to OIE (2012).

**Experimental design**

Sixty, 4 weeks old specific pathogen free (SPF) chickens (were obtained from Kom Osheem farm in Fayoum, Egypt) were divided into four groups (15 chickens for each group), the 1<sup>st</sup> group was vaccinated with *M. gallisepticum* vaccine, the 2<sup>nd</sup> group was vaccinated with combined vaccine of *M. gallisepticum* and *P. multocida*, the 3<sup>rd</sup> group was vaccinated with imported inactivated *M. gallisepticum* vaccine and the 4<sup>th</sup> group was kept unvaccinated as a control group. The vaccinated chickens were received vaccines in a dose of 0.5 ml in 2 doses with 1 month interval. Blood samples were collected at 3<sup>rd</sup>, 7<sup>th</sup> and 15<sup>th</sup> days after second vaccination and after challenge for the determination of the cellular immunity by measurement of nitric oxide (NO) in the supernatant of macrophage according to Rajaraman et al., (1998) and Municio et al., (2013). Also serum samples were collected every 2 weeks till 25 weeks of age for the determination of the humoral immune response of the vaccinated chickens by Enzyme Linked Immuno sorbent assay (ELISA) technique (*M. gallisepticum* antibody test kit; Proflok®, Synbiotics® Corporation, No. 96-6533). At the same time the vaccine was evaluated by challenge test (at 11 weeks of age) against the challenge with the virulent strain of *M. gallisepticum* (Eis3-10 strain) according to Whithear (1996).

**RESULTS AND DISCUSSION**

For many years, the control of *M. gallisepticum* in most of the world has been based on the maintenance of breeding stock that is free of *M. gallisepticum* and on biosecurity (Ley, 2008). However, *M. gallisepticum* vaccines may be employed in situations where this approach is not feasible such as endemically infected multi-age facilities and areas of dense poultry populations (Kleven, 2008). While *M. gallisepticum* bacterins reduced the severity of lesions and egg production losses but did not completely prevent *M. gallisepticum* colonization of the chicken respiratory tract upon challenge (OIE, 2012).

*M. gallisepticum* is further complicated with other poultry pathogens causing avian influenza, New Castle disease, infectious bronchitis, fowl cholera, coryza and *E. coli* (Liu et al., 2001). So this study was conducted for preparation of locally prepared combined inactivated vaccine of *M. gallisepticum* and *P. multocida* adjuvanted with Montanide ISA70, evaluation of it and comparison of its efficacy with the imported *M. gallisepticum*
vaccine.

<table>
<thead>
<tr>
<th>Interval times of blood collection</th>
<th>Types of vaccines</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>M. gallisepticum</td>
</tr>
<tr>
<td>Pre vaccination</td>
<td>10.9</td>
</tr>
<tr>
<td>Post 2nd vaccination</td>
<td></td>
</tr>
<tr>
<td>At 3rd day</td>
<td>19.7</td>
</tr>
<tr>
<td>At 7th day</td>
<td>45.2</td>
</tr>
<tr>
<td>At 15th day</td>
<td>29.4</td>
</tr>
</tbody>
</table>

| Challenge                         |                  |                  |                  |         |
| At 3rd day                        | 23.3             | 47.8             | 41.5             | 11.7    |
| At 7th day                        | 78.3             | 102.6            | 94.1             | 15.2    |
| At 15th day                       | 44.7             | 74.6             | 62.7             | 10.8    |
| Overall means                     | 35.9             | 52.4             | 46.6             | 12.4    |

Table (1): Concentration of NO in the supernatant of macrophage:

NO: nitric oxide

Cellular immune response of chickens that vaccinated with different M. gallisepticum vaccines was evaluated by estimation of NO concentration in the supernatant of macrophage (Table 1). Group of chickens vaccinated with combined M. gallisepticum and P. multocida vaccine showed a significant increase of overall mean of concentration of NO in supernatant of macrophage. These data were in the same manner with Obukhovska et al., (2015) who concluded that the level of macrophages in chickens increased rapidly during the first 10 days after the second injection of inactivated M. gallisepticum vaccines adjuvanted with Mantanide ISA70. It was shown that inoculation of inactivated vaccines against avian mycoplasmosis in chickens promoted stimulation for primary link of cellular immunity (macrophage).

These data were explained by Zhang et al., (2013) who stated that the capsule is a major virulence factor of P. multocida serotype A: 3 strain. Also Harper et al., (2013) reported that P. multocida is a Gram-negative pathogen and the causative agent of fowl cholera and the major outer membrane component LPS is both an important virulence factor and a major immunogen.

Nascimento et al., (2005) stated that genus Mycoplasma has ability to stimulate macrophages, monocytes, T-helper cells and NK cells, results in the production of substances, such as tumor necrosing factor (TNF-α), interleukin (IL-1, 2, 6) and interferon (α, β, γ). Moreover Majumder (2014) explained that M. gallisepticum cytadheres to the tracheal epithelium and mediates infiltration of macrophages, heterophils and lymphocytes to the tracheal submucosa.

The humoral immune response of the vaccinated chickens with different M. gallisepticum vaccines was evaluated by ELISA as illustrated in Table (2) noticed that a significant increase of the overall mean of the antibody titers against M. gallisepticum by ELISA test was in the group of chickens vaccinated with combined M. gallisepticum and P. multocida vaccine. These data agreed with Gondal et al., (2013) and Bekele (2015) who reported that the formaldehyde inactivated Montanide ISA70 based M. gallisepticum vaccine induced protective level of anti M. gallisepticum antibodies in chickens. Also Sarfaraz et al., (2017) reported that oil based combined M. gallisepticum and avian influenza (H9N2) vaccine adjuvanted with Montanide ISA-70 induced effective antibody response in the vaccinated birds measured by ELISA and haemaglutination inhibition (HI) tests.

These data were explained by Harper et al., (2012) who reported that the capsule and LPS of P. multocida constitute the major components of the bacterial cell surface. They play key roles in a range of interactions between the bacteria and the hosts they colonize or infect. Both polysaccharides are involved in the avoidance of host innate immune mechanisms, such as resistance to phagocytosis, complement-mediated killing, and the bactericidal activity of antimicrobial peptides; they are therefore essential for virulence. In addition, LPS is a major antigen in the stimulation of adaptive immune responses to infection.

Potency of the vaccines were evaluated by the challenge test against M. gallisepticum (Eis3-10 strain) in chickens vaccinated with different M. gallisepticum vaccines was illustrated in Table (3) showed that the protection percentage (P %) against the challenge with M. gallisepticum was 93% for combined M. gallisepticum and P. multocida vaccine.
Table (2): Level of antibody titers against *M. gallisepticum* by ELISA:

<table>
<thead>
<tr>
<th>Interval times of blood collection</th>
<th>Types of vaccines</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><em>M. gallisepticum</em></td>
<td>Combined vaccine</td>
<td>Imported vaccine</td>
<td>Control</td>
</tr>
<tr>
<td>Pre vaccination</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>1&lt;sup&gt;st&lt;/sup&gt; vaccination</td>
<td>157</td>
<td>360</td>
<td>241</td>
<td>0</td>
</tr>
<tr>
<td>Booster vaccination (at 4 weeks post 1&lt;sup&gt;st&lt;/sup&gt; vaccination)</td>
<td>729</td>
<td>996</td>
<td>965</td>
<td>0</td>
</tr>
<tr>
<td>9&lt;sup&gt;th&lt;/sup&gt; vaccination</td>
<td>1039</td>
<td>1902</td>
<td>1636</td>
<td>0</td>
</tr>
<tr>
<td>11&lt;sup&gt;th&lt;/sup&gt; vaccination</td>
<td>2423</td>
<td>4166</td>
<td>3665</td>
<td>0</td>
</tr>
<tr>
<td>13&lt;sup&gt;th&lt;/sup&gt; vaccination</td>
<td>2541</td>
<td>4958</td>
<td>3927</td>
<td>0</td>
</tr>
<tr>
<td>15&lt;sup&gt;th&lt;/sup&gt; vaccination</td>
<td>2106</td>
<td>3551</td>
<td>3229</td>
<td>0</td>
</tr>
<tr>
<td>17&lt;sup&gt;th&lt;/sup&gt; vaccination</td>
<td>1624</td>
<td>2768</td>
<td>2199</td>
<td>0</td>
</tr>
<tr>
<td>19&lt;sup&gt;th&lt;/sup&gt; vaccination</td>
<td>1010</td>
<td>1860</td>
<td>1487</td>
<td>0</td>
</tr>
<tr>
<td>21&lt;sup&gt;st&lt;/sup&gt; vaccination</td>
<td>743</td>
<td>969</td>
<td>892</td>
<td>0</td>
</tr>
<tr>
<td>Overall means</td>
<td>1237</td>
<td>2153</td>
<td>1824</td>
<td>0</td>
</tr>
</tbody>
</table>

Table (3): Challenge test against *M. gallisepticum* (Eis3-10 strain):

<table>
<thead>
<tr>
<th>Types of vaccines</th>
<th><em>M. gallisepticum</em></th>
<th>Combined vaccine</th>
<th>Imported vaccine</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total no. of chickens</td>
<td>15</td>
<td>15</td>
<td>15</td>
<td>15</td>
</tr>
<tr>
<td>No. of chickens showing respiratory signs</td>
<td>3</td>
<td>1</td>
<td>2</td>
<td>15</td>
</tr>
<tr>
<td>Protection%</td>
<td>80</td>
<td>93</td>
<td>87</td>
<td>0</td>
</tr>
</tbody>
</table>

These data were in the same manner with those of Bekele (2015) who concluded that the formaldehyde inactivated Montanide ISA70 based *M. gallisepticum* vaccine induced 100% protection against *M. gallisepticum*. All chickens did not show clinical signs or post mortem changes after challenge test. Also Ferguson-Noel et al., (2012) found that the *M. gallisepticum* bacterin was protective and resulted in significant differences in air sac lesions, tracheal lesions, and ovarian regression compared to the non-vaccinated controls.

Moreover Shafay (1995) concluded that the locally prepared combined inactivated vaccine of *M. gallisepticum* and *P. multocida* gave acceptable protection level in comparison with the monovalent *M. gallisepticum* vaccine in vaccinated chickens. Also Gadallah (2015) reported that the locally prepared inactivated combined *M. gallisepticum* and *E. coli* vaccine induced protection against the chronic respiratory disease and elicited the humoral immune response in broiler chickens.

These data were explained by Gong et al., (2013) who stated that two outer membrane proteins (OmpH and OmpA) are the major immunogenic antigens of avian *P. multocida*, which play an important role in inducing immune responses that confer resistance against infections. Moreover Boyle and Finlay (2003) found that the outer membrane proteins promote adherence to host cell surfaces and are therefore likely to be involved in *P. multocida* virulence. Also Noor mohammadi (2007) found that lipoproteins (LPs) reside on the surfaces of the cell wall-less mycoplasmas and are important factors in pathogenesis.

**CONCLUSION**

So it could be concluded that the locally prepared combined inactivated *M. gallisepticum* and *P. multocida* vaccine induced a considerable immunity in chickens as it gave early, high and long duration of antibody response. Also it was efficient and safe in protection of chickens against *M. gallisepticum* and *P. multocida* infections. Depending on this study, it could be suggested to use this combined vaccine for control of *M. gallisepticum* in poultry industry.

**CONFLICT OF INTEREST**

The authors declared that present study was performed in absence of any conflict of interest*.

**ACKNOWLEDGEMENT**

I would like to thank Aerobic Bacterial Vaccines Department, Veterinary Serum and Vaccine Research Institute, Abbasia, Cairo, Egypt and Mycoplasma Department, Animal Health...
Research Institute, Dokki, Giza, Egypt for covering all the expenses of the experiment needed to conduct the work.

AUTHOR CONTRIBUTIONS
FF performed the experiments and wrote the manuscript. EI-JJ, WAA and EM designed the experiments and reviewed the manuscript. MM and FF designed the experiments and prepared the vaccine. All authors read and approved the final version.

Copyrights: © 2017 @ author(s).
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

REFERENCES
Mukkur TKS, Pyliotis NA, Bones A. 1982. Possible immunological synergism among
the protective antigens of P. multocida type A. Comp Pathol 92: 249-260.


